Advertorial
CHAMPION-AF study of the WATCHMAN FLX™ Left Atrial Appendage Closure Device as a first-line therapy for stroke risk reduction meets all primary and secondary safety and efficacy endpoints
Boston Scientific Corporation (PRNewsFoto/Boston Scientific Corporation) (PRNewsFoto/Boston Scientific Corporation) (PRNewsfoto/Boston Scientific Corporation)
As featured on
Global randomized trial demonstrated statistically significant reduction in clinical event r…
Data highlights the WATCHMAN FLX device provided statistically superior protection from blee…
